<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826887</url>
  </required_header>
  <id_info>
    <org_study_id>GU-EN-Solep-01</org_study_id>
    <nct_id>NCT04826887</nct_id>
  </id_info>
  <brief_title>SOLTIVE™ Laser Enucleation for Treatment of Benign Prostatic Hyperplasia</brief_title>
  <official_title>SOLTIVE™ Laser Enucleation for Treatment of Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare intraoperative as well as postoperative outcomes of SOLTIVE Thulium Fiber Laser&#xD;
      Enucleation of the Prostate (ThuFLEP) vs Holmium Laser Enucleation of the Prostate.&#xD;
&#xD;
      Our hypothesis is that utilizing the SOLTIVE Thulium laser enucleation of the prostate will&#xD;
      result in a more efficient procedure, comparable results to that of Holmium laser enucleation&#xD;
      of the prostate and subjective improvement of prior device limitations&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thulium laser is continuous wave laser which offers numerous potential benefits compared to&#xD;
      alternative lasers and surgical procedures used for BPH. The SOLTIVE Laser system is a&#xD;
      compact system which is significantly smaller than Holmium laser systems. The laser fiber is&#xD;
      also smaller in diameter allowing for improved maneuverability with decreased fiber&#xD;
      degradation and endoscope damage. The continuous wave pattern produces fast, hemostatic cuts&#xD;
      during the removal and furthermore the associated hemostasis improves the visual field.&#xD;
      Additionally, based on the 1940nm wavelength is absorbed nearly five times more in water. For&#xD;
      all the stated reasons, the SOLTIVE Thulium Laser should improve the enucleation efficiency&#xD;
      and warrants further investigation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 29, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Comparing the SOLTIVE Thulium Fiber to the Holmium Laser for HoLEP</measure>
    <time_frame>up to 1 year</time_frame>
    <description>To evaluate SOLTIVE Thulium Fiber Laser Enucleation of the Prostate (ThuFLEP) in comparison to Holmium Laser Enucleation of the Prostate through AUA Symptom Score. AUA Symptom score will be assessed using the Scale - Mild (under 7 cumulative score, moderate 8-19 score, and severe is a cumulative score over 20).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare intraoperative components between the two surgical approaches</measure>
    <time_frame>up to 1 year</time_frame>
    <description>To compare intraoperative components of SOLTIVE Thulium Fiber Laser Enucleation of the Prostate (ThuFLEP) vs Holmium Laser Enucleation of the Prostate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare post-operative outcomes of the two surgical approaches</measure>
    <time_frame>up to 2 years</time_frame>
    <description>To compare post-operative components of SOLTIVE Thulium Fiber Laser Enucleation of the Prostate (ThuFLEP)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>BPH</condition>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Solep Arm</arm_group_label>
    <description>Use of SOLTIVE Thulium Laser for HoLEP (Holmium Laser Enucleation of the Prostate) procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <description>Use of Holmium Laser for HoLEP (Holmium Laser Enucleation of the Prostate) procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SOLTIVE Thulium Laser</intervention_name>
    <description>Use of SOLTIVE Thulium laser for HoLEP</description>
    <arm_group_label>Solep Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care (Holmium Laser)</intervention_name>
    <description>Use of Holmium laser for HoLEP</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will present to clinic for treatment of BPH assessment and evaluation per routine&#xD;
        clinical care. Patients will be identified by clinical care team as an eligible candidate&#xD;
        for study participation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be 18 years of age or older&#xD;
&#xD;
          2. Patients must be diagnosed with benign prostatic hyperplasia&#xD;
&#xD;
          3. Patients must opt for surgical management of their BPH with laser enucleation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a concomitant neurogenic bladder diagnosis (SCI, Parkinson, MS, cerebral&#xD;
             palsy)&#xD;
&#xD;
          2. Patients with prostate glands greater or equal to 200 grams&#xD;
&#xD;
          3. Patients who are enrolled in other surgical or interventional trials at the time of&#xD;
             this study are not eligible.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Study is looking at benign prostatic hypeplasia (BPH) - therefore men are the only gender to enroll. Women do not have prostates</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Neff</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medcial Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Don Neff, MD, FACS</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

